Clinical Trial: NCT04531046
Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | The Lymphoma Academic Research Organisation |
| Information Provided By: | The Lymphoma Academic Research Organisation |
| Last Update Posted: | 2026-03-27 |
Study Overview
Brief Summary
This is a phase 2, open-label, multicenter study evaluating axicabtagene ciloleucel (axi-cel) as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible to receive Autologous Stem Cell Transplantation but eligible to receive CAR T-cell therapy.
Official Title
Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation
Conditions
B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Intervention / Treatment
- Drug: axicabtagene ciloleucel
Other Study ID Numbers
- ALYCANTE
Start Date (Actual)
2021-03-10
Primary Completion Date (Actual)
2022-04-19
Study Completion Date (Estimated)
2026-06
Enrollment (Actual)
62
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | The Lymphoma Academic Research Organisation |
| Information Provided By: | The Lymphoma Academic Research Organisation |
| Last Update Posted: | 2026-03-27 |
Study Overview
Brief Summary
This is a phase 2, open-label, multicenter study evaluating axicabtagene ciloleucel (axi-cel) as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible to receive Autologous Stem Cell Transplantation but eligible to receive CAR T-cell therapy.
Official Title
Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation
Conditions
B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Intervention / Treatment
- Drug: axicabtagene ciloleucel
Other Study ID Numbers
- ALYCANTE
Start Date (Actual)
2021-03-10
Primary Completion Date (Actual)
2022-04-19
Study Completion Date (Estimated)
2026-06
Enrollment (Actual)
62
Study Type
Interventional
Phase
Phase 2